Drug intelligence / Profile preview

BNT153

Development stage: Phase 1
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

BNT153 is a nucleoside-modified mRNA-based drug developed by BioNTech. It encodes for human interleukin-2 (IL-2), a cytokine that plays a key role in immune system activation. Upon administration, the mRNA is taken up by cells and translated into IL-2 protein, which then targets and binds to the IL-2 receptor beta subunit (IL2Rb) on immune cells. This stimulates an immunostimulatory response aimed at enhancing anti-tumor immunity. The drug is being investigated primarily as an immunotherapy for advanced solid tumors in patients who have no standard treatment options likely to confer clinical benefit[1][3][4].

Other names: ribocytokine IL-2 BNT153HUMAN INTERLEUKIN-2 MRNA-ENCODED BNT153

Targets

IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on BNT153.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT153.

Explore the full profile